Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Common Equity (2020 - 2025)

Historic Common Equity for Relay Therapeutics (RLAY) over the last 6 years, with Q3 2025 value amounting to $607.7 million.

  • Relay Therapeutics' Common Equity fell 2755.55% to $607.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $607.7 million, marking a year-over-year decrease of 2755.55%. This contributed to the annual value of $777.8 million for FY2024, which is 342.94% up from last year.
  • Per Relay Therapeutics' latest filing, its Common Equity stood at $607.7 million for Q3 2025, which was down 2755.55% from $665.7 million recorded in Q2 2025.
  • In the past 5 years, Relay Therapeutics' Common Equity ranged from a high of $999.8 million in Q3 2022 and a low of $571.1 million during Q3 2021
  • Its 5-year average for Common Equity is $771.3 million, with a median of $777.8 million in 2024.
  • In the last 5 years, Relay Therapeutics' Common Equity surged by 46213.61% in 2021 and then crashed by 2755.55% in 2025.
  • Quarter analysis of 5 years shows Relay Therapeutics' Common Equity stood at $897.8 million in 2021, then rose by 5.84% to $950.2 million in 2022, then decreased by 20.86% to $752.0 million in 2023, then grew by 3.43% to $777.8 million in 2024, then dropped by 21.87% to $607.7 million in 2025.
  • Its Common Equity was $607.7 million in Q3 2025, compared to $665.7 million in Q2 2025 and $721.1 million in Q1 2025.